Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: rhythmtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $70.00 | Buy | Guggenheim |
| 9/18/2024 | $64.00 | Buy | H.C. Wainwright |
| 9/17/2024 | $64.00 | Mkt Outperform | JMP Securities |
| 5/8/2024 | $49.00 → $42.00 | Buy → Neutral | BofA Securities |
| 12/19/2023 | $29.00 → $55.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/1/2023 | $22.00 → $27.00 | Neutral → Buy | BofA Securities |
| 1/18/2023 | $52.00 | Buy | Canaccord Genuity |
| 8/8/2022 | $28.00 | Neutral → Buy | Goldman |
| 8/5/2022 | $8.00 → $20.00 | Underperform → Neutral | BofA Securities |
| 6/17/2022 | $40.00 → $25.00 | Buy | Needham |
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
10-Q - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
10-Q/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity -- BOSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data that showed four pediatric patients with acquired hypothalamic obesity or congenital hypothalamic obesity achieved >5% weight reduction at t
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology. "Severe, early-onse
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on November 7, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,750 shares of its common stock to three new employees. These inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards to in
-- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program -- -- Top-line data readout for Phase 3 trial evaluating setmelanotide in 120 patients with acquired hypothalamic obesity on track for 1H 2025 -- -- sNDA to expand IMCIVREE label to include patients as young as 2 years old in approved indications accepted by FDA for Priority Review with PDUFA goal date of Dec. 26, 2024 -- -- Cash on-hand expected to support planned operations into 2026 -- -- Management to host conferenc
-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months -- -- Greater reduction in fat mass (29.7%) versus reduction in lean muscle mass (7.7%) reported from Phase 2 trial extension in patients with acquired hypothalamic obesity (n=11) after 12 months -- -- Positive data from Phase 2 DAYBREAK stage 2 showed mean BMI reduction of 12.4% in patients with rare MC4R pathway diseases on continuous setmelanotide therapy for 40 weeks (n=32) -- -- New Phase 3 VENTURE trial data showed mean BMI reduction of 23.8% in pediatric patient
BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Axovia Therapeutics Ltd. today announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS). "We believe there is a significant need and opportunity with the growing awareness of BBS to better understand the disease and its epidemiology," said Prof. Phil Beales, Axovia Therapeutics' Chief Executive Officer and Co-Founder. "At Axovia, we are utilizing gene therapy to address the loss of sight and obesity experienced by patients with BBS, and we are pleased to be collaborating with Rhythm, a global company that has pioneered research in the mel
-- Five posters to be presented at ObesityWeek® -- BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 5:00 p.m. ET on Tuesday, November 5, 2024 to report its third quarter 2024 financial results and provide a corporate update. The conference call will be hosted live from The Obesity Society's Annual Meeting, ObesityWeek® in San Antonio, TX. To access the live conference call, participants may register here. While not required, it is recommended that pa
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on October 4, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 30,050 shares of its common stock to nine new employees. These inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,450 shares of its common stock to four new employees. These inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards to
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 -- BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (P
SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13D/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13D/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13D/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13D - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
SC 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
-- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program -- -- Top-line data readout for Phase 3 trial evaluating setmelanotide in 120 patients with acquired hypothalamic obesity on track for 1H 2025 -- -- sNDA to expand IMCIVREE label to include patients as young as 2 years old in approved indications accepted by FDA for Priority Review with PDUFA goal date of Dec. 26, 2024 -- -- Cash on-hand expected to support planned operations into 2026 -- -- Management to host conferenc
-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months -- -- Greater reduction in fat mass (29.7%) versus reduction in lean muscle mass (7.7%) reported from Phase 2 trial extension in patients with acquired hypothalamic obesity (n=11) after 12 months -- -- Positive data from Phase 2 DAYBREAK stage 2 showed mean BMI reduction of 12.4% in patients with rare MC4R pathway diseases on continuous setmelanotide therapy for 40 weeks (n=32) -- -- New Phase 3 VENTURE trial data showed mean BMI reduction of 23.8% in pediatric patient
-- Five posters to be presented at ObesityWeek® -- BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 5:00 p.m. ET on Tuesday, November 5, 2024 to report its third quarter 2024 financial results and provide a corporate update. The conference call will be hosted live from The Obesity Society's Annual Meeting, ObesityWeek® in San Antonio, TX. To access the live conference call, participants may register here. While not required, it is recommended that pa
-- Second quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $29.1 million -- -- Dosed first patients in supplemental, 12-patient Japanese cohort in global Phase 3 trial evaluating setmelanotide in hypothalamic obesity; On track for topline data from 120-patient, pivotal cohort in 1H 2025 -- -- Completed sNDA submission seeking to expand U.S. label of IMCIVREE to treat pediatric patients as young as 2 years old in approved indications -- -- Cash on-hand expected to support planned operations into 2026 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chi
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chief
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Cha
-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint -- -- Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS -- -- RM-718 showed potential to reduce body weight and hyperphagia with no off-target cardiovascular effects and no hyperpigmentation observed in pre-clinical studies; first in-human studies anticipated to begin in the first half of 2024 -- -- Responder rates of 25 to 56 percent demonstrated in six genetic cohorts of Phase 2 DAYBREAK trial of setmelanotide -- -- Company to host R&D webcast toda
-- Third quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVREE therapy -- -- Phase 3 hypothalamic obesity trial on track to be fully enrolled by the end of 2023 -- -- 25.5% mean BMI reduction achieved at one year of setmelanotide therapy in patients with hypothalamic obesity (n=12) who transitioned to long term extension from Ph 2 trial; three of 11 pediatric patients achieving normal body weight at one year on setmelanotide treatment -- -- Cash on-hand of $299.3 million sufficient to fund planned operations into 2026 -- -- Company to provide update on R&D programs for inve
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 7, 2023 to report its third quarter 2023 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhyt
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired
ZUG, Switzerland, Jan. 5, 2021 /PRNewswire/ -- Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced two key appointments to its Board of Directors: David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director. Dr. Meeker currently serves as the President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM). Dr. Glassman currently serves as a Public Equity Venture Partner at OrbiMed Advisors. "Both David and Robert are incredibly talented, passionate and admire
Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $55.5, a high estimate of $79.00, and a low estimate of $42.00. Th
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $46 to $55.
-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company's Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypothalamic obesity.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE (setmelanotide) include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
Including Options For 9,230 Shares And RSUs For 46,850 Shares
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications -- Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3 2024 -- Preclinical data demonstrated potential of RM-718 to reduce body weight and hunger -- Additional posters feature design of Phase 1 trial of RM-718 and real-world RESTORE study -
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.
B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the price target from $49 to $42.
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $50 to $46.
Guggenheim initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $70.00
H.C. Wainwright initiated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $64.00
JMP Securities initiated coverage of Rhythm Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $64.00
BofA Securities downgraded Rhythm Pharmaceuticals from Buy to Neutral and set a new price target of $42.00 from $49.00 previously
Morgan Stanley upgraded Rhythm Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $55.00 from $29.00 previously
BofA Securities upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $27.00 from $22.00 previously
Canaccord Genuity resumed coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $52.00
Goldman upgraded Rhythm Pharmaceuticals from Neutral to Buy and set a new price target of $28.00
BofA Securities upgraded Rhythm Pharmaceuticals from Underperform to Neutral and set a new price target of $20.00 from $8.00 previously
Needham reiterated coverage of Rhythm Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $40.00 previously